Table 3.
Symptom experience at the 21-day follow-up interview by medication use group
| Medication use group | |||||
|---|---|---|---|---|---|
| Stopped Side Effects SS (n=89) | Stopped Other Reasons SO (n=79) | Never Took NT (n=32) | Continued to Take CT (n=817)* | ||
| Symptom experience in last month | No. (%) | No. (%) | No. (%) | No. (%) | Overall P value |
| Probable medication side effects | |||||
| Nauseaa,b,e,f | 62 (70) | 34 (43) | 7 (23) | 475 (58) | <.001 |
| Flatulenceb,f | 53 (60) | 35 (44) | 8 (26) | 456 (56) | .001 |
| Changes in dreamingb,d,f | 48 (55) | 40 (51) | 6 (20) | 471 (58) | <.001 |
| Change in appetitea,e | 46 (52) | 25 (32) | 12 (39) | 401 (49) | .01 |
| Dysgeusiab,f | 44 (50) | 27 (34) | 5 (16) | 385 (48) | <.001 |
| Difficulty sleepingb | 46 (52) | 26 (33) | 7 (23) | 350 (43) | .01 |
| Constipation | 28 (31) | 23 (29) | 5 (16) | 266 (33) | .25 |
| Retchinga,c | 24 (27) | 6 (8) | 2 (6) | 68 (8) | <.001 |
| Vomitinga,c | 19 (21) | 3 (4) | 2 (6) | 76 (9) | <.001 |
| Probable nicotine withdrawal symptoms | |||||
| Desire to smoke | 64 (72) | 64 (81) | 27 (87) | 639 (79) | .27 |
| Tension/agitation | 46 (53) | 36 (46) | 15 (48) | 368 (45) | .53 |
| Irritability/anger | 40 (46) | 34 (43) | 13 (42) | 345 (42) | .93 |
| Anxietyc,f | 44 (50) | 28 (35) | 17 (55) | 262 (32) | <.001 |
| Difficulty concentratingc | 39 (44) | 21 (27) | 7 (23) | 222 (27) | .007 |
| Depression | 27 (30) | 15 (19) | 9 (29) | 183 (23) | .22 |
| Confusion | 21 (24) | 8 (10) | 4 (13) | 113 (14) | .05 |
| “Other”a,b'c | 31 (35) | 10 (13) | 3 (10) | 208 (26) | <.001 |
*
One person responded “don’t know” when asked if still taking varenicline.
Overall p-value for chi-square comparing the four medication use groups on each symptom. Significant pairwise comparisons, after adjustment for multiple comparisons:
a
SS vs. SO;
b
SS vs. NT;
c
SS vs. CT;
d
SO vs. NT;
e
SO vs. CT;
f
NT vs. CT.